Browse Category

NASDAQ:LEGN News 8 December 2025 - 7 January 2026

Legend Biotech stock hits a fresh 52-week low as biotech lags — JPMorgan update looms

Legend Biotech stock hits a fresh 52-week low as biotech lags — JPMorgan update looms

Legend Biotech shares dropped 4.7% to $20.49 Monday, hitting a 52-week low and leaving the stock down 55% from its high. The decline comes ahead of the J.P. Morgan Healthcare Conference, where CEO Ying Huang is set to present Jan. 14. Broader biotech stocks also fell, with key ETFs down about 1%. Investors are watching for updates on CARVYKTI, Legend’s CAR-T therapy for multiple myeloma.
5 January 2026
Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

U.S. stocks are trading in a holding pattern on Wednesday, December 10, 2025, as Wall Street waits for the Federal Reserve’s final interest‑rate decision of the year. Index moves are modest, but beneath the surface a cluster of mid‑cap names is posting double‑digit percentage declines, led by Dyne Therapeutics (DYN), SLM Corp (SLM), Kontoor Brands (KTB) and Waystar Holding (WAY). Investing.com+1 According to real‑time data from StockScan, the 10 biggest U.S. stock losers today by percentage move (among actively traded listed shares) are: StockScan Below is a breakdown of what’s driving today’s biggest losers, plus how they fit into the
Legend Biotech (LEGN) Stock Hits New Lows: Oversold CAR-T Leader or Long-Term Opportunity?

Legend Biotech (LEGN) Stock Hits New Lows: Oversold CAR-T Leader or Long-Term Opportunity?

As of December 9, 2025, shares of Legend Biotech Corporation (NASDAQ: LEGN) are under heavy pressure even as the company posts strong growth from its flagship CAR-T therapy, CARVYKTI. Here’s a deep dive into the latest news, forecasts, analyst calls and technical signals that are driving sentiment around Legend Biotech stock today. Where Legend Biotech Stock Trades Now Legend Biotech’s American Depositary Shares (ADS) were recently trading around $24.1, down roughly 8% on the day and hovering near fresh 52-week lows. Benzinga On December 9, 2025, the stock: A company news brief from Investing.com highlighted that Legend Biotech shares hit
9 December 2025
Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech Corp. (NASDAQ: LEGN) shares are under heavy pressure on December 8, 2025, trading in the mid‑$20s and touching a new 52‑week low around $25.66 during the session. The slide comes despite strong clinical momentum for its flagship CAR‑T therapy CARVYKTI® and robust revenue growth, as investors react to valuation resets and ongoing concerns about profitability and cash flow. Investing.com+1 This article rounds up the key news and analysis on Legend Biotech stock from December 8, 2025 and the days immediately preceding it, and looks at what Wall Street expects next for LEGN. Disclaimer: This article is for information
Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)

Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)

Wall Street kicked off “Fed week” in a cautious mood on Monday, December 8, 2025. U.S. stock futures ticked slightly higher, with the S&P 500 hovering just below record territory as traders priced in an ~85–90% chance of another 25‑basis‑point rate cut at the Federal Reserve’s final meeting of the year. TechStock²+1 Beneath that calm index-level picture, several individual U.S. stocks logged outsized losses, led by biotech, AI‑chip, consumer staples and med‑tech names. According to TipRanks’ “Stock Market Losers Today” screen for U.S. equities (data from late morning Eastern time), the day’s biggest percentage decliners included: TipRanks Below is a closer look at the key stories, forecasts and analyst commentary behind the

Stock Market Today

Intel stock price jumps to $50: China CPU delays and SambaNova funding set up week ahead

Intel stock price jumps to $50: China CPU delays and SambaNova funding set up week ahead

8 February 2026
Intel shares rose 4.9% to $50.59 Friday, tracking a 5.7% jump in the PHLX semiconductor index as investors bet on AI-driven data-center spending. Reuters reported Intel and AMD warned Chinese customers of tighter server CPU supply, pushing Intel’s China prices up over 10%. Intel expects supply to improve in Q2. After the bell, Reuters said Intel plans to invest about $100 million in AI chip startup SambaNova Systems.
Go toTop